All patients
Age < 65y (younger) Age > 65y Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage M0/M1A/M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/adv melanoma (mML), ipilimumab plus gp100 vs. vaccine, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
0.68 [0.55 ; 0.85 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 539 NA not evaluable DORdetailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
0.68 [0.55 ; 0.85 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 25 NA not evaluable objective responses (ORR)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 4.06 [0.94; 17.43]
4.06 [0.94 ; 17.43 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 539 NA not evaluable AE (any grade)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.95 [0.54; 7.01]
1.95 [0.54 ; 7.01 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.94 [0.63; 1.40]
0.94 [0.63 ; 1.40 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable TRAE (any grade)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 2.17 [1.28; 3.67]
2.17 [1.28 ; 3.67 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.64 [0.90; 2.99]
1.64 [0.90 ; 2.99 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable TRAE leading to death (grade 5)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.36 [0.28; 6.47]
1.36 [0.28 ; 6.47 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 539 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
1.39 [0.06 ; 31.06 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Colitis TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 8.58 [0.50; 146.20]
8.58 [0.50 ; 146.20 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 5.01 [0.65; 38.48]
5.01 [0.65 ; 38.48 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 2.80 [0.15; 53.28]
2.80 [0.15 ; 53.28 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 8.05 [1.07; 60.32]
8.05 [1.07 ; 60.32 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
0.69 [0.02 ; 20.81 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
0.46 [0.10 ; 2.07 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
1.39 [0.06 ; 31.06 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
0.69 [0.02 ; 20.81 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Increase AST TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.17 [0.02; 1.91]
0.17 [0.02 ; 1.91 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
1.39 [0.06 ; 31.06 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Pruritus TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
0.69 [0.02 ; 20.81 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Rash TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 3.51 [0.19; 64.62]
3.51 [0.19 ; 64.62 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 6.38 [0.37; 110.82]
6.38 [0.37 ; 110.82 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.35 [0.01; 17.55]
0.35 [0.01 ; 17.55 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Abdominal pain AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.29 [0.09; 0.87]
0.29 [0.09 ; 0.87 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Anaemia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.33 [0.14; 0.78]
0.33 [0.14 ; 0.78 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Constipation AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.04 [0.11; 10.11]
1.04 [0.11 ; 10.11 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Cough AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
0.69 [0.02 ; 20.81 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Decreased appetite AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.51 [0.14; 1.85]
0.51 [0.14 ; 1.85 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Diarrhoea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 6.13 [0.81; 46.56]
6.13 [0.81 ; 46.56 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Dyspnoea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.80 [0.30; 2.14]
0.80 [0.30 ; 2.14 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Fatigue AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.68 [0.56; 5.04]
1.68 [0.56 ; 5.04 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Headache AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
0.46 [0.10 ; 2.07 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Nausea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.17; 2.80]
0.69 [0.17 ; 2.80 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Pyrexia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.34 [0.05; 2.47]
0.34 [0.05 ; 2.47 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable Vomiting AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.81 [0.21; 3.17]
0.81 [0.21 ; 3.17 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 512 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 23:17 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 549